AVENIO ctDNA Targeted Kit V2
Overview
The AVENIO ctDNA Targeted Kit V2 is a next-generation sequencing (NGS) liquid biopsy assay that contains 17 genes, including those in U.S. National Comprehensive Cancer Network (NCCN) Guidelines.1 The Targeted panel may be used for pan-cancer research applications, but is specially optimized for lung cancer and colorectal cancer (CRC) research. The AVENIO ctDNA Targeted Kit V2 is an efficient tumor profiling solution.
Features and Benefits
- Includes genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines1
- All four mutation classes (SNVs, indels, fusions and CNVs) in a single assay
- Exceptional analytical performance supported by integrated digital error suppression (iDES) strategies combining molecular barcodes with in silico error suppression techniques2,3
- Includes reagents, bioinformatics and software
- Streamlined, end-to-end research workflow from extraction to analysis and reporting in five days
Exceptional Performance3
The AVENIO family of NGS oncology assays
The AVENIO ctDNA Targeted Kit V2 is a part of the AVENIO family of NGS oncology research assays that include three ctDNA and three corresponding tumor tissue assays. By using the wider family of AVENIO assays, labs can obtain detailed molecular findings across all four mutation classes from plasma or tissue samples.
References
- National Comprehensive Cancer Network. Accessed August 2, 2023
- Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Medicine. 2014;20(5):548–554 doi:10.1038/nm.3519
- Data on file with Roche.